AI Article Synopsis
- The PedArPan project tested a children's version of the modular model predictive control (MMPC) algorithm in children aged 5 to 9 with type 1 diabetes during a camp outing.
- In a randomized trial with 30 participants, the artificial pancreas (AP) was compared to parent-managed sensor-augmented pump (SAP) over six days.
- Results indicated that the AP significantly reduced overnight hypoglycemia but also led to higher average glucose levels and slightly decreased time within the target glucose range, suggesting that algorithm improvements are needed for better efficacy.
Article Abstract
Objective: The Pediatric Artificial Pancreas (PedArPan) project tested a children-specific version of the modular model predictive control (MMPC) algorithm in 5- to 9-year-old children during a camp.
Research Design And Methods: A total of 30 children, 5- to 9-years old, with type 1 diabetes completed an outpatient, open-label, randomized, crossover trial. Three days with an artificial pancreas (AP) were compared with three days of parent-managed sensor-augmented pump (SAP).
Results: Overnight time-in-hypoglycemia was reduced with the AP versus SAP, median (25(th)-75(th) percentiles): 0.0% (0.0-2.2) vs. 2.2% (0.0-12.3) (P = 0.002), without a significant change of time-in-target, mean: 56.0% (SD 22.5) vs. 59.7% (21.2) (P = 0.430), but with increased mean glucose 173 mg/dL (36) vs. 150 mg/dL (39) (P = 0.002). Overall, the AP granted a threefold reduction of time-in-hypoglycemia (P < 0.001) at the cost of decreased time-in-target, 56.8% (13.5) vs. 63.1% (11.0) (P = 0.022) and increased mean glucose 169 mg/dL (23) vs. 147 mg/dL (23) (P < 0.001).
Conclusions: This trial, the first outpatient single-hormone AP trial in a population of this age, shows feasibility and safety of MMPC in young children. Algorithm retuning will be performed to improve efficacy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2337/dc15-2815 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
AI-Driven insights in pancreatic cancer imaging: from pre-diagnostic detection to prognostication.
Abdom Radiol (NY)
December 2024
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the United States, largely due to its poor five-year survival rate and frequent late-stage diagnosis. A significant barrier to early detection even in high-risk cohorts is that the pancreas often appears morphologically normal during the pre-diagnostic phase. Yet, the disease can progress rapidly from subclinical stages to widespread metastasis, undermining the effectiveness of screening.
View Article and Find Full Text PDFMulti-omic markers of Intraductal Papillary Mucinous Neoplasms progression into pancreatic cancer.
Semin Cancer Biol
December 2024
Department of Biology, University of Pisa, Pisa, Italy. Electronic address:
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal and common form of pancreatic cancer, it has no specific symptoms, and most of the patients are diagnosed when the disease is already at an advanced stage. Chemotherapy typically has only a modest effect, making surgery the most effective treatment option. However, only a small percentage of patients are amenable to surgery.
View Article and Find Full Text PDFGeneration of vascularized pancreatic progenitors through co-differentiation of endoderm and mesoderm from human pluripotent stem cells.
Stem Cell Res Ther
December 2024
Department of Central Laboratory, Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen, Guangdong, China.
Background: The simultaneous differentiation of human pluripotent stem cells (hPSCs) into both endodermal and mesodermal lineages is crucial for developing complex, vascularized tissues, yet poses significant challenges. This study explores a method for co-differentiation of mesoderm and endoderm, and their subsequent differentiation into pancreatic progenitors (PP) with endothelial cells (EC).
Methods: Two hPSC lines were utilized.
Impact of pre- and post-exercise strategies on hypoglycemic risk for two modalities of aerobic exercise among adults and adolescents living with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized controlled trial.
Diabetes Metab
December 2024
Institut de recherches cliniques de Montréal, Canada; Département de Nutrition, Faculté de Médecine, Université de Montréal, Canada; Endocrinology Division and Montreal Diabetes Research Center, Canada. Electronic address:
Objective: We investigated strategies to mitigate hypoglycemic risk during and after different aerobic exercises in people with type 1 diabetes (pwT1D) using continuous subcutaneous insulin infusion.
Research Design And Methods: Thirty-seven pwT1D (21 adults, 16 adolescents; HbA1c = 7.5 ± 1.
DLLabelsCT: Annotation tool using deep transfer learning to assist in creating new datasets from abdominal computed tomography scans, case study: Pancreas.
PLoS One
December 2024
Research Unit of Translational Medicine, Oulu University Hospital, Oulu, Finland.
The utilization of artificial intelligence (AI) is expanding significantly within medical research and, to some extent, in clinical practice. Deep learning (DL) applications, which use large convolutional neural networks (CNN), hold considerable potential, especially in optimizing radiological evaluations. However, training DL algorithms to clinical standards requires extensive datasets, and their processing is labor-intensive.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!